Simultaneous diagnosis of allergic bronchopulmonary aspergillosis and Mycobacterium avium complex lung disease

BMJ Case Rep. 2023 Sep 26;16(9):e255845. doi: 10.1136/bcr-2023-255845.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) and Mycobacterium avium complex lung disease (MAC-LD) often coexist because bronchiectasis, caused by ABPA or MAC, might be an important predisposing factor for both conditions. Here, we describe a man with asthma symptoms who had centrilobular small nodules and mucoid impaction on chest CT. We diagnosed the patient with simultaneous ABPA and MAC-LD on the basis of bronchoscopy findings. Itraconazole monotherapy led to substantial clinical improvement, avoiding the adverse effects of systemic corticosteroids. Sputum culture conversion of MAC was achieved after switching from itraconazole monotherapy to combination therapy comprising clarithromycin, rifampicin and ethambutol. ABPA recurred but was controlled by reinitiation of itraconazole. Overall, corticosteroid management was avoided for 38 months. Itraconazole monotherapy may be selected as initial treatment for ABPA with chronic infection, including MAC.

Keywords: Asthma; Bronchitis; Infections; Pneumonia (infectious disease).

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Aspergillosis, Allergic Bronchopulmonary* / complications
  • Aspergillosis, Allergic Bronchopulmonary* / diagnosis
  • Aspergillosis, Allergic Bronchopulmonary* / drug therapy
  • Humans
  • Itraconazole / therapeutic use
  • Lung Diseases* / complications
  • Male
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection* / complications
  • Mycobacterium avium-intracellulare Infection* / diagnosis
  • Mycobacterium avium-intracellulare Infection* / drug therapy

Substances

  • Itraconazole
  • Adrenal Cortex Hormones